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ABSTRACT 
Objective: Quetiapine fumarate (QF) has poor water solubility and its oral bioavailability is observed to be 9% [1]. The objective of the present 
work is to prepare QF nanoparticles by wet media milling (WMM) and explore on the improvement in solubility with the aim of dose reduction and 
minimizing the side effects associated with its oral administration. 
Methods: Nanoparticle of QF were prepared by WMM using sodiumlaurylsulphate (SLS), polyvinylpyrrolidone (PVP), hydroxypropylcellulose 
(HPC) and Hydroxypropylmethylcellulose (HPMC) as surface stabilizers. The nanosuspensions obtained were characterized for its mean particle 
size (MPS), zeta-potential (ZP) and Polydispersity-index (PI). Further lyophilized nanoparticles were characterized for MPS, ZP, PI, saturation 
solubility (SS), X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC), Infra-Red (IR) and Scanning electron Microscopy (SEM). 
Results: The MPS of the nanosuspensions obtained after 1 hour WMM and its lyophilized nanoparticlesis observed to be less than 1000 nm with PI 
ranges from 0.2 to 0.6 and negative ZP ranging from -30 to -36 mV. Lyophilized nanoparticles have shown significant improvement in SS when 
compared to plain drug. XRD and DSC have shown absence of the crystalline peaks and endotherm of QF respectively, indicating loss of its 
crystallinity. IR spectra showed no change in position of bands thus drug is compatible with surface stabilizers used. SEM photographs confirmed 
the formation of nanoparticles.  
Conclusion: From the above results it has been concluded that by subjecting QF to WMM, QF nanoparticles were obtained with significant 
improvement in saturation solubility and drug losing its crystalline nature when compared to plain drug. 
Keywords: Quetiapine Fumarate, Nanosuspension, Wet media milling, Lyophilized nanoparticles. 
 
INTRODUCTION 
A significant percentage of active pharmaceutical ingredients 
identified through discovery screening programs are poorly soluble 
in water. These molecules are often difficult to formulate using 
conventional approaches and are associated with innumerable 
formulation-related performance issues, e.g. poor bioavailability, 
lack of dose proportionality, slow onset of action and other 
attributes leading to poor patient compliance[2]. Most of the 
synthetic drug available so far in market are either weakly acidic or 
basic in nature, such molecules possess narrow range of absorption 
profile [3], when administered orally for systemic therapies. The 
erratic and poor absorption of these molecules are closely related 
with different physiological pH of gastrointestinal tract. Poor 
solubility in water correlates with poor bioavailability. If there is no 
way to improve drug solubility it will not be able to be absorbed 
from the gastrointestinal tract into the bloodstream and reach the 
site of action. A major hurdle that has prevented commercialization 
of many promising poorly soluble drugs is dissolution rate limited 
bioavailability [4]. There is a continuous need for improving 
bioavailability of such molecules.  
The conventional approaches to solve the problems of low solubility 
and low bioavailability include micronization, use of fatty solutions, 
use of penetration enhancer or co-solvents, surfactant dispersion 
method, salt formation, precipitation, etc., but still, these techniques 
having limited utility in solubility enhancement for poorly soluble 
drugs. Additional approaches are vesicular system like liposomes, 
dispersion of solids, emulsion and micro-emulsion methods, and 
inclusion complexes with cyclodextrins, which show beneficial effect 
as drug delivery system but major problems of these techniques are 
lack of universal applicability to all drugs [5]. Nanoparticles are 
gaining the pharmaceutical industry’s attention as research and 
practical experience demonstrate their many uses. [6]. The oral, 
parenteral, transdermal, transmucosal, ocular, and pulmonary drug-
delivery routes can effectively use nanoparticles, and implants can 
incorporate these particles, too. In a 2007 study, research firm 
Fredonia Group concluded that demand for nanotech-based medical 
supplies and devices in the US will exceed a value of $110 billion by 
2016. 
Over the last decades, nanoparticle engineering has been developed 
and has been reported for pharmaceutical applications [7]. The 
various advantages of nanosuspension include, enhance the 
solubility and bioavailability of drugs, suitable for hydrophilic drugs, 
higher drug loading can be achieved, dose reduction is possible, 
enhance the physical and chemical stability of drugs, provides a 
passive drug targeting [8]. 
Drug nanocrystals are one of the most important strategies to 
enhance the oral bioavailability of the hydrophobic drug. Drug 
particle size reduction has been often used to enhance the solubility 
as per Noyes-Whitney equation [9]. Increasing surface area by 
producing smaller drug particles is one of the main strategies to 
improve the solubility and/or bioavailability but the smaller 
particles aggregate and reduce the surface area for wetting and 
dissolution. Hence stabilizing the nanoparticles poses challenge in 
the development of nanoformulations [10].  
Creating nanoparticles can be challenging and requires appropriate 
equipment and techniques. There are various ways in which 
nanoparticles of poorly water-soluble molecules are generated such 
as a) Wet Media Milling/ WMM (also called as bead milling or pearl 
milling or nano milling) b) High pressure homogenization, c)Solvent 
evaporation, d) Nanoprecipitation, e) Emulsification/solvent, 
f)diffusion, g) Salting out, h) Dialysis, i) Supercritical fluid 
technology (SCF) [11].  
Bead or Pearl milling is perhaps the most established technique for 
the production of drug nanocrystals and has been described in detail 
in several recently published reviews [12, 13, 14 ]. Media milling or 
wet grinding is the best-established manufacturing method for 
nanoparticle production. Its many benefits include, excellent 
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particle-size control, cost-effectiveness, equipment scalability from 
bench-top to production, limited or no contamination of the active 
ingredient, process repeatability, fulfillment of current good 
manufacturing practice production requirements. Media milling 
involves the use of various milling media such as zirconia, and glass 
balls/beads to reduce the particle size of the compounds and 
produce sub-micron particle dispersions [15].In brief, pearl milling 
involves the continuous stirring and wet milling of aqueous drug 
slurry with specialized—and extremely hard and durable milling 
beads. Nanocrystals which are smaller than 1000 nm in diameter 
may be produced, and particle size reduction is achieved via a 
combination of high-energy shear and impaction forces between the 
milling pearls and the solid drug particles. The addition of a surface 
stabilizer(s) to the aqueous drug slurry is essential as this attenuates 
the increase in free energy associated with the creation of new 
particle surface and prevents nanocrystals aggregation. 
With the proper stabilizing agents, bead mills efficiently disperse 
output to discrete, sub micrometer particle-size, stable dispersion. 
In bead mills, impact and shearing forces between moving beads 
grind suspended solid particles. The agitator shaft within the 
machine’s stator housing transmits kinetic energy to the grinding 
media.Stress intensity and the number of contact points are the 
main factors that determine particle fineness. Stress intensity is 
influenced by the kinetic energy in the grinding beads. To produce a 
fine particle-size distribution, a process must have a high number of 
contact points. The smaller the grinding media, the more contact 
points touch the product. Mostly the particle size achieved by media 
milling is equal to 1/1000 the size of the grinding media. 
The formulation consists only of water, drug and one or more 
excipients acting as surface stabilizers. Typically, on average, the 
drug to stabilizer ratio on a weight basis ranges from 1:1 to 20:1. 
These liquid nanosuspension exhibit acceptable shelf-life and can be 
post-processed into various types of solid dosage forms. 
Nanoparticulate based drug products have been shown to improve 
bioavailability and enhance drug exposure for oral and parenteral 
dosage forms. Quetiapine is an psychotropic agent used for 
treatment of schizophrenia, bipolar disorder and major depressive 
disorder. 
 During the Fourth Quarter of 2009 quetiapine ranked third on the 
list of top 40 brand name drugs. Adverse metabolic effects of 
atypical antipsychotics include diabetes mellitus, lipid 
abnormalities, weight gain, metabolic and cardiovascular effects. 
The relative risk of glucose intolerance/diabetes mellitus, 
hyperlipidemia and hyper-leptinemia are moderately high for 
quetiapine[16].The recommended dosage of quetiapine is 800 mg 
per day. Fatal overdoses associated with quetiapine have been 
reported [17]. 
Quetiapine was BCS Class IV drug having low solubility and low 
permeability so to solve this problem Fumarate salt was prepared 
which increase the permeability of Quetiapine but solubility remains 
the same. Thus Quetiapine was converted to Quetiapine Fumarate 
which is a BCS Class II drug having low solubility and high 
permeability, thus making it suitable for nanosizing. Quetiapine 
fumarate is a weak acid which exhibits moderate pH dependent 
solubility and lipophilicity characteristics, thus quetiapine shows pH 
dependent solubility i.e. it is soluble in acidic aqueous media but 
solubility of drug decreases with increase in pH of media. However 
its oral bioavailability has been reported to be 9 %. In the present 
study, an attempt is made to improve the solubility of QF by 
reducing the particle size to nanosize (i.e. below 1000 nm). Wet 
Media Milling technique was used to prepare nanoparticles and 
study its characterization data. The nanoparticles prepared were 
characterized for particle size, zeta potential and saturation 
solubility to confirm improvement in the solubility and also 
characterized by XRD, DSC, IR and SEM to study the morphology of 
quetiapine fumarate before and after particle size reduction. 
MATERIALS AND METHODS 
Quetiapine fumarate was obtained from Dr Reddys laboratories 
limited, Hydroxy propyl methylcellulose (HPMC 6 cps) supplied by 
Colorcon Private Limited, polyvinylpyrrolidone (PVP) supplied by 
BASF, hydroxyl propyl cellulose (HPC) supplied by Hercules, sodium 
lauryl sulfate(SLS) supplied by JRS. All other chemicals and solvents 
used are of analytical grade. 
Preparation of Nanoparticles 
QF nanosuspensions were prepared by using different surface 
stabilizers such as SLS, PVP, HPC and HPMC as indicated in Table 1. 
Drug suspensions were prepared by dissolving SLS and polymer 
stabilizers (PVP/HPMC/HPC) in small quantity of purified water 
with stirring. To this drug QF was dispersed in small quantities with 
slow stirring. The drug suspension was subjected to high shear 
homogenization for about 10 minutes to prevent any lump 
formation and uniform mixing. The drug suspension was then 
subjected to size reduction by using WMM technique. 
QF nanosuspensions were prepared by using a bead mill (Model: 
Lab Star 1, NietzscheMill and Germany). The milling chamber was 
charged with the milling or grinding media comprising of 0.5 mm 
Yttrium stabilized zirconium beads that constituted up to 80% 
occupancy of chamber. The milling operation was performed in a re-
circulation mode with the suspension fed at a rate of 115 gram per 
minute. The mill and pump speeds were set at 1800 and 50 rpm 
respectively. The suspension flowed axially through the milling 
chamber where the shear forces generated during impaction of the 
milling media with the drug provided the energy input to fracture 
the drug crystals into nanometer-sized particles. The temperature 
inside the milling chamber was maintained at 20 ± 2°C by circulating 
cooling water through the outer jacket. After milling, the suspension 
was collected and stored at a temperature below 25°C until further 
processing. Initial sample (i.e. before milling) and for every 15 
minutes the sample has been collected for particle size and zeta 
potential analysis. 
Table 1: Composition of quetiapine nanosuspension 
Formulation Drug 
(%) 
SLS PVP HPC HPMC Water 
QF-01 5 1 3 - - qs 
QF-03 5 1 - - 3 qs 
QF-07 5 1 - 3 - qs 
 
Production of dry nanoparticles 
The nanosuspensions prepared were lyophilized using lyophilizer. 
The samples were kept in deep freezer at -70 °C overnight and kept 
in lyophilizer at -33 °C for about 11.25 hours, -5 °C for 24 hours,20 
°C for 3 hours and 40 °C for 11 hours. Total freeze drying cycle time 
is not less than 42.28 hours.  
Characterization of nanosuspension and lyophilized 
nanoparticles 
The particle size, particle size distribution, and zeta potential affect 
the safety, efficacy, and stability of nanodrug delivery systems as 
well as solubility is also altered by solid state of nanoparticles. Thus, 
characterization of nanoparticles plays a great role in forecasting in 
vitro and in vivo performance of nanodrug delivery systems. In vivo 
pharmacokinetic performance and biological function of 
nanosuspension strongly depends on its particle size and 
distribution, particle charge (zeta potential), crystalline state, and 
particle morphology[18]. 
Particle size analysis 
The MPS and particle size distribution (PSD) affects saturation 
solubility of nanoparticles. The particle size distribution and its 
range named Polydispersity index (PI) can be determined by laser 
diffraction (LD), photon correlation spectroscopy, microscope, and 
coulter counter [19].PI gives the physical stability of 
nanosuspensions and should be as lower as possible for the long-
time stability of nanosuspensions. A PI value of 0.1 to 0.25 shows a 
fairly narrow size distribution and PI value more than 0.5 indicates a 
very broad distribution [20]. 
The particle size distribution of suspension before (initial), during 
(at different time intervals of milling ie 15 minutes, 30 minutes, 45 
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minutes) and completion of milling (60 minutes)were determined 
using Malvern Zetasizer Nanoseries nano-ZS. The particle diameter 
reported was calculated based on size distribution by intensity. A 
refractive index of 1.65 has been used for measurements. The 
particle size obtained with different stabilizer compositions was 
evaluated. The nanosuspension was diluted with water to obtain 
suitable concentrations for measurement. Diluted nanosuspension 
was added to the sample cell (quartz cuvette) and put into sample 
holder unit and measurement was carried out with help of software. 
The particle size of drug in lyophilized sample was analyzed by 
adding water to lyophilized sample (so that the surface stabilizers 
are in dissolved state and only drug in dispersed form) followed by 
dilution with water to obtain suitable concentrations for 
measurement. 
Zeta potential 
A prerequisite to achieve an enhancement of oral bioavailability 
with drug nanocrystals is that crystals are finely dispersed in the gut 
and do not aggregate. In case they start aggregation, the 
bioavailability decreases with increasing aggregate formation. This 
is attributed to the fact that they lose special properties of 
nanoparticles such as their adhesive property to the mucosal wall. 
Therefore it is necessary to prepare nanosuspensions with a 
physical stability as high as possible. Surface charge properties of 
the nanosuspensions are studied through zeta potential. The value 
of particle surface charge indicates the stability of nanosuspensions 
at the macroscopic level. A minimum zeta potential of ±30 mV is 
required for electrostatically stabilized nanosuspensions [21, 22] 
and a minimum of ±20 mV for steric stabilization [23]. The zeta 
potential values are commonly calculated by determining the 
particle's electrophoretic mobility and then converting the 
electrophoretic mobility to the zeta potential [24]. 
Zeta potential of the suspension before, during and after milling has 
been analyzed in Malvern zeta sizer after diluting nanosuspension 
with water to obtain suitable concentration for measurement. Water 
was added to the lyophilized samples and diluted with water to 
obtain suitable concentration for measurement. Zeta potential of the 
optimized formulation was measured using the same instrument. 
Sample was added in specialized zeta cell and the same procedure as 
that of particle size was carried out. 
Saturation Solubility 
Saturation solubility was carried out in different media (different 
pH) conditions using rotary shake flask method. Different pH 
media’s include 0.1 N hydrochloric acid (HCl), 4.5 phosphate buffer, 
6.8 phosphate buffer and purified water. Excess amount of drug and 
lyophilized nanoparticles have been added to 100 ml of media 
maintained at 37 °C and shaken on rotary shake flask for a period of 
24 hours. The samples were taken into centrifuge tube and 
centrifuged for about 10 minutes at 4000 rpm.  
The supernatant was diluted with diluent (methanol and acetonitrile 
in 1:1 ratio)and analyzed using HPLC (Waters Alliance HPLC system, 
USA) method. The mobile phase consists of mixture of potassium 
dihydrogen orthophosphate, acetonitrile, tetrahydrofuran, triethyl 
amine pH adjusted to 6.4 with KOH solution. Chromatographic 
separation was accomplished using an Xterra Column RP8 3.5 µm; 
4.6X150 mm column. The mobile phase was pumped isocratically at 
a flow rate of 1.5 mL/minute during analysis and maintained at a 
column temperature of 50°C. 
Powder X-day diffraction [PXRD] 
Polymorphic or morphological changes of nanosized particles can be 
checked by assessing the crystalline state and particle morphology 
[25].As nanosuspension formation experiences high attrition during 
bead milling, change in crystalline structure of formulation occurs 
which may be converted to either amorphous or other polymorphic 
forms [26,27] Alteration in the solid state of the drug particles and 
the extent of the amorphous portion is determined by X-ray 
diffraction analysis [28] and supplemented by Differential Scanning 
Calorimetry analysis. The X-ray diffractograms of QF and the 
lyophilized nanoparticles were recorded using a Panalytical X-pert 
Pro, Diffractometer, Netherlands) with a Cu line as the source of 
radiation. Standard runs using a 40 kV voltage, a 40mA current and a 
scanning rate of 0.02°min−1 over a 2θ range of 3 – 45° were used 
Differential Scanning Calorimetry [29] 
Thermal characteristics of the QF, physical mixtures of QF, PVP, SLS 
and lyophilized nanoparticles were studied.Thermal properties of 
powder samples were investigated using a Perkin-Elmer DSC-7 
differential scanningcalorimeter / TAC-7 thermal analysis controller 
with an intracooler-2 cooling system (Perkin- ElmerInstruments, 
USA). For evaluation about 3 to 5 mg of product was placed in 
perforated aluminumsealed 50 microliterpans and the heat runs for 
each sample was set from 20 to 200°C at 10°C/minute, an 
inertenvironment was maintained using nitrogen.  
Fourier Transforms Infra –Red Spectroscopy 
The infrared spectra are recorded on Fourier Transform 
Spectrometer in mid infrared with in the range (400-4000 cm-1). 
Due to the complex interaction of atoms with in the molecule, IR 
absorption of the functional groups may vary over a wide range. 
However, it has been found that many functional groups give 
characteristic IR absorption at specific narrow frequency range. 
Multiple functional groups may absorb at one particular frequency 
range but a functional group often gives rise to several characteristic 
absorptions. Stretching & bending vibrations are varied after 
formulation can be observed. Thus, the spectral interpretations 
should not be confined to one or two bands only actually the whole 
spectrum should be examined [30,31]. 
FT- IR spectra of quetiapine fumarate, excipients and lyophilized 
samples were recorded on the sample prepared in Potassium 
Bromide (KBr) disks, wherein sample and KBr are taken in 1:100 
ratio) using Shimadzu Fourier Transform Infra-Red spectrometer. 
The samples were scanned over a frequency range 4000-400 cm-1. 
Scanning electron Microscopy 
Scanning electron microscopy is a type of electron microscopy that 
images the surface of solid specimen by using focused beam of high-
energy electrons. Scanning electron microscopy (SEM) is giving 
morphological examination with direct visualization. The techniques 
based on electron microscopy offer several advantages in 
morphological and sizing analysis; however, they provide limited 
information about the size distribution and true population average. 
For SEM characterization, nano particles solution should be first 
converted into a dry powder, which is then mounted on a sample 
holder followed by coating with a conductive metal.  
The sample is then scanned with a focused fine beam of electrons 
[32].The electrons which are scattered and/or generated through 
secondary processes, are collected through secondary electron or 
back-scattered electron detectors. The backscattered electron 
images are sensitive to the atomic weight of the elements present. 
The regions of the image which appear brighter indicate the 
presence of high atomic weight elements. The surface characteristics 
of the sample are obtained from the secondary electrons emitted 
from the sample surface. The nanoparticles must be able to 
withstand vacuum, and the electron beam can damage the 
polymer[33]. 
Quetiapine Fumarate or the lyophilized sample powder was placed 
on the Carbon tape stuck to the Aluminum SEM stub. Later it was 
imaged in the SEM at a low vacuum. The particle size analysis of 
lyophilized Nanosuspension was carried out to confirm the nano-
size of formulation.The nanosuspension of quetiapine fumarate 
prior to lyophilization was also analyzed by scanning electron 
microscopy to study the surface properties. Nanosuspension was 
dried on thin glass slide which is placed on the Carbon tape stuck to 
the Aluminum SEM stub. Later it was imaged in the SEM at a low 
vacuum.  
RESULTS AND DISCUSSION 
Nanoparticles of QF were successfully prepared by wet media 
milling technique. The obtained nanoparticles have been assessed 
for particle size analysis, zeta potential, saturation solubility and 
solid state characterization by XRD, DSC, IR and SEM analysis. 
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Particle size analysis 
The particle size of the nanosuspension and the lyophilized 
nanoparticles was analyzed by zeta sizer. All samples at different 
time points of milling were analyzed for particle size after dilution 
with water. The MPS (nm) and PI of nanosuspensions at different 
time points of milling is represented in (Table 2).  
From the results it could be inferred that after 1 hour of WMM the 
particle size in the nanosize was obtained.  
The MPS obtained after 60 minutes of WMM is ranging from75 nm 
to 409 nm and PI is ranging from 0.2 to 0.6. The particle size 
distribution pattern of QF-01 after 60 minutes WMM with MPS of 
75.3 nm is shown in figure 1. 
 
Table 2: Mean particle size (MPS) and Polydispersity index (PDI) of nanosuspensions 
Nanosuspensions Initial 15 min 30 min 45 min 60 min 
 MPS (nm) PDI MPS (nm) PDI MPS (nm) PDI MPS (nm) PDI MPS (nm) PDI 
QF-01 1728 0.930 649 0.57 231.6 0.283 209.9 0.27 75.3 0.28 
QF-03 2324 1.0 924 0.71 494 0.627 385.6 0.643 305 0.61 
QF-07 1928 1.0 860 0.71 741 0.873 663 0.53 409.4 0.565 
 
 
Fig. 1: Particle size graph of QF-01after 60 minutes of WMM 
The MPS (nm) and PI of dried nanoparticles obtained after lyophilization 
of nanosuspensions prepared is represented in (Table 3). 
 




QF-01  QF-03  QF-07  
 MPS(nm) PDI MPS(nm) PDI MPS(nm) PDI 
60 
minutes 
163 0.5 325 0.4   
 
Zeta potential 
Zeta potential of nanosuspensions prepared by using and 
electrostatic stabilizer (SLS) and steric stabilizers (PVP/HPC/HPMC) 
was measured using zeta sizer. The zetapotential of the 
nanosuspensions and lyophilized nanoparticles measured has been 
tabulated in (Table 4).  
Zeta potential of the nanosuspension was found to be more than -30 
mV (in the range of -30 mV to -36 mV) indicating the stability of the 
nanosuspensions formed. Further the zeta potential of the 
lyophilized nanoparticle prepared for batch QF-01 was observed to 
be -34 mV as shown in figure 2, indicating the stability of the 
lyophilized nanoparticles obtained. 
 
Table 4: Zeta potential (-mV) of the Quetiapine 
nanosuspensionsand Quetiapine nanoparticles 
Time (minutes) QF-01 QF-03 QF-07 
Quetiapine Nanosuspension 
Initial 36 30 31.4 
60  32 32 32.5 
Quetiapine Nanoparticles [Lyophilized] 
60 minutes 34 - - 
 
Fig. 2: Zeta potential distribution of lyophilized nanoparticles 
from batch QF-01 
 
The narrowest particle size distribution and smallest particle size of 
nanosuspensions was observed for composition with SLS and PVP as 
surface stabilizers ie batch QF-01 with SLS and PVP as stabilizers 
achieved particle size 75.3 nm after 60 minutes of media milling and 
the zeta potential before and after lyophilization more than -30 mV 
which is attributed to better stability. Hence batch QF-01 has been 
taken forward for saturation solubility analysis and solid state 
characterization. 
Saturation Solubility 
The Saturation solubility of pure drug and lyophilized nanoparticles 
from QF-02 was evaluated in 0.1N HCl, phosphate buffer pH 4.5, 
phosphate buffer pH 6.8 and water at physiological temperature 
(37°C). The higher solubility in acidic pH (0.1N HCl) condition as 
compared to phosphate buffer pH 6.8 or water could be attributed to 
the pH dependent solubility of quetiapine fumarate. It has been 
observed that the saturation solubility of lyophilized nanoparticles 
was significantly higher than as-is drug at all pH conditions as 
shown in Figure 3. 
 
 
Fig. 3: Saturation solubility of Quetiapine Fumarate and 
Quetiapine lyophilized nanoparticles. 
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Solid state characterization 
Quetiapine fumarate, Quetiapine lyophilized nanoparticles has been 
subjected to various solid state characterizations such as XRD, DSC, 
IR and SEM analysis. 
X-day diffraction [XRD] 
The presence of numerous distinct peaks in the X-ray diffraction 
pattern indicate that QF as crystalline material with characteristic 
diffraction peaks appearing at a diffraction angle of 2θ at 7.4, 16.26, 
20.1, 23.29& 38.23. The powder X-ray diffraction pattern of the 
quetiapine fumarate is shown in (Figure 4A) and quetiapine 
lyophilized nanoparticlesis shown in (Figure4B). From the data it 
has been observed that quetiapine lyophilized nanoparticles showed 
complete absence of the characterized peaks of quetiapine fumarate. 
The results indicate that quetiapine fumarate is no longer in 





Fig. 4: XRD pattern of A [QF], B[lyophilized nanoparticles] 
 
FTIR Spectroscopy 
Figure 5 shows that IR spectrum of the QF (5A), SLS (5B), PVP (5C), 
physical mixture of SLS+PVP (5D), physical mixture of QF+SLS+PVP 
(5E) and the Quetiapine lyophilized nanoparticles (5F). The 
characteristic peaks of QF observed at 3310 cm-1may be due to O-H 
stretching, 3080 cm-1 may be due to Ar-H stretching; 2880 cm-1 due 
to C-H stretching, 1600 cm-1 may be due to C-N, 1597, N-H 
bending;1340 cm-1 maybe due to C-H; bending, 1070 cm-1 C-C 
stretching, 1030 cm-1 may be due to –C-O-C group, 791 cm-1 may be 
due to substituted benzene ring; The peaks of 1647, 1463 and 1294 
cm-1 are assigned to the C=O stretching, CH2 bending and C-N 
stretching vibration, respectively in the PVP. The absorption peaks 
at 1407 cm -1
 
may be attributed to -S-O stretching of sodium lauryl 
sulphate. From the IR spectrums of the QF, individual excipients, 
physical mixture and the lyophilized nano particles, it has been 
observed that there is no appreciable change in the positions of the 
characteristic bands of the drug either in physical mixture or during 
lyophilization. Since there is no change in the nature and position of 
the bands in the formulation, it can be concluded that the drug 
maintains its identity without going any chemical interaction with 












Fig. 5: IR spectra of A [QF]; B [SLS]; C [PVP]; D [PM of SLS+PVP]; 
E [PM of QF+ SLS+PVP]; F [lyophilized nanoparticles] 
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Differential Scanning Calorimetry 
The DSC thermograms of pure drug quetiapine fumarate, physical 
mixture of QF+PVP+SLS and lyophilized nanoparticles were 
obtained as shown in figure 6. The thermograms obtained by DSC 
studies, reveal that the melting point of pure drug QF is 175 °C. The 
physical mixture gave melting endotherm at 170 °C for QF and broad 
melting endotherm at 74.89 for PVP.  
The thermogram of lyophilized nanoparticles haveshown broad 
endotherm only at 70 °C and complete absence of endotherm related 
to QF indicating the loss of drug crystallinity of drug. These results 
confirm that QF is no longer present as crystalline form when 
processed by WMM.  
 
 
Fig. 6: DSC thermograms of drug QF (A), physical mixture (B) 
and lyophilized nanoparticles (C) 
 
Scanning Electron Microscopy [SEM] 
Pure drug quetiapine fumarate, nanosuspension and its lyophilized 
nanoparticles were been analyzed for surface appearance, particle 
size and shape by Scanning electron microscopy. Pure quetiapine 
fumarate showed crystalline particles with particle size ranging 
from 12 to 44 microns. SEM photograph of quetiapine fumarate at 
higher magnification (A) and lower magnification are shown in 
Figure 7. 
 
A   B 
Fig. 7: SEM Photographs of Quetiapine Fumarate at different 
magnification 
 
The SEM photographs of the nanosuspensions were also obtained. 
The SEM photographs of the nanosuspensions at higher (A) and 
lower (B) magnification are shown in Figure 8.The SEM photographs 
of nanosuspension clearly indicate the change in the morphology of 
QF wherein crystalline irregular shaped particles of QF changed to 
spherical particles. The SEM photographs of the lyophilized 
nanoparticles were also obtained at lower (A) and higher (B) 
magnification as shown in Figure 9. The lyophilized nanoparticles 
when analyzed by SEM confirmed the formation of nanoparticles of 
quetiapine fumarate wherein particle size less than 1000 nm 
(ranging from 412 nm to 847 nm). 
 
A   B 




A   B 
Fig. 9: SEM photograph of theQuetiapine lyophilized 
nanoparticles 
 
The SEM photographs of dried nanosuspension (as shown in Figure 
8) and lyophilized nanoparticle (as shown in Figure 9) illustrate the 
stabilizers (PVP and SLS) precipitated around the drug 
nanoparticles during water removal process (i.e. lyophilization), 
thus creating highly hydrophilic environment around quetiapine 
fumarate and preventing particle interaction. 
CONCLUSION 
In this study quetiapine nanoparticles were successfully prepared by 
wet media milling and were evaluated for its various solid state 
characteristics. Wet media milling was shown to be simple and adequate 
operation for particle size reduction. Through various studies performed 
it was found that crystalline quetiapine fumarate lost its crystallinity and 
shown improved saturation solubility. The increase in the solubility can 
be expected to have a significant impact in the oral bioavailability of the 
drug. This study shows the effectiveness of the wet media milling 
technique as a promising approach for enhancement of the solubility of 
poorly soluble drug like quetiapine fumarate. 
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